Unlock instant, AI-driven research and patent intelligence for your innovation.

Linagliptin crystal form, and preparation method therefor

A technology of linagliptin crystal and linagliptin, which is applied in the field of linagliptin crystal form and preparation thereof, can solve the problems of polymorph transformation, difficulty in ensuring, and polymorph ratio change, and achieves thermal stability. Excellent stability

Inactive Publication Date: 2018-07-17
HANMI FINE CHEM
View PDF14 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the preparation process, there may be a process of stirring, drying, and pulverizing the mixture containing the raw material drug. Due to the heat generated in this process, the polymorphic form may change or the ratio between polymorphic forms may occur. change question
In addition, it is difficult to ensure that the prepared pharmaceutical formulations still maintain a certain polymorph or maintain a certain ratio between polymorphs during storage at room temperature.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Linagliptin crystal form, and preparation method therefor
  • Linagliptin crystal form, and preparation method therefor
  • Linagliptin crystal form, and preparation method therefor

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0045] Specifically, the preparation method of the linagliptin crystal form includes (1) adding the linagliptin 4-hydroxybenzoate into water or an organic solvent, and then adding a base and then stirring; and (2) filtering the reactant in the step (1), washing the filtered crystal with water and an organic solvent, and drying.

[0046]In the step (1), the solvent may be alcohol such as methanol or ethanol, acetone, water, etc., and water alone is preferably used. The use of water dissolves various bases and in this way avoids the use of various types of organic solvents commonly used to produce known crystalline forms and allows the separation of residual acids. Based on the volume of linagliptin 4-hydroxybenzoate, the solvent can be used in an amount of 5 to 20 times the volume, preferably 8 to 15 times the volume.

[0047] In addition, the base can be basified with linagliptin 4-hydroxybenzoate to form a linagliptin crystal form. The base can be an organic base or an inorg...

Embodiment 1

[0064] Embodiment 1: Preparation of linagliptin 4-hydroxybenzoate

[0065] 30 g of linagliptin (Intercore Corporation) was added to the reactor, and 240 ml of ethanol solvent was added thereto, and the reaction mixture was heated to about 70° C. and completely dissolved by stirring for about 15 minutes. After adjusting the temperature of the dissolved reaction solution to about 60° C., 1 equivalent of 4-hydroxybenzoic acid was added to the clear reaction solution. After stirring at the same temperature for about 4 hours, the resulting crystals were filtered, washed with 90ml of ethanol, and dried under warm air at about 60°C to obtain 34.8g of linagliptin 4-hydroxybenzoate (yield: 90 %, purity: 88.2% (4-hydroxybenzoic acid 11.6%), melting point: 204°C).

[0066] 1H-NMR (DMSO-d6, 300MHz) δ8.22(d, 1H), 7.89(dd, 1H, J=5.4Hz), 7.80-7.74(m, 3H), 7.65(dd, 1H, J=5.4Hz ),6.76(d,2H),5.31(s,2H),4.90(s,2H),3.68(d,2H),3.56(d,2H),3.38(s,3H),3.07-2.99(m, 2H),2.93-2.90(m,1H),2.87(s,3H),1....

Embodiment 2

[0067] Example 2: Preparation of linagliptin crystal form-(1)

[0068] Add 20.0 g of linagliptin 4-hydroxybenzoate prepared in Example 1 to the reactor, dissolve 12.0 g of sodium hydroxide in 300 ml of water to prepare an aqueous solution, and add it to the reactor. After stirring at about 25° C. for 15 minutes, the reaction mixture was filtered, washed with 200 ml of water, and dried under warm air at about 60° C. to obtain 14.0 g of a solid compound (yield: 91%). Then, 10 g of the solid compound was added into the reactor, 100 ml of water was added, and stirred at about 25° C. for 10 minutes. The reaction mixture was filtered, washed with 100 ml of water, and then washed with 50 ml of heptane, and then dried in vacuum at about 60° C. to obtain 9.29 g of linagliptin crystal form. (Yield: 93%, purity: 99.8%, melting point: 202°C).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a linagliptin crystal form, and a preparation method therefor. According to the present invention, the linagliptin crystal form has excellent thermal stability and canbe reproducibly prepared into a single crystal form, thereby enabling mass production with consistent quality, and thus can be useful as a pharmaceutical composition for treating diabetes.

Description

Technical field [0001] The present invention relates to a new crystalline form of linagliptin and a preparation method thereof, as well as a pharmaceutical composition for treating diabetes containing the component as an active ingredient. Background technique [0002] Linagliptin (8-[(3R)-3-amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4 -Methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione) is being effectively used as a raw material for diabetes treatment. [0003] As a therapeutic agent for type 2 diabetes, linagliptin was approved by the U.S. Food and Drug Administration in 2011 and is currently sold around the world under the trade name Linagliptin. TM (tradjenta) sales. [0004] Diabetes is divided into two types according to its mechanism: type 1 diabetes, in which beta cells are destroyed and insulin is not secreted at all, and type 2 diabetes, in which insulin action is reduced due to insulin resistance and insulin cannot be secreted fully. Currently,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D473/04A61K31/522C07D403/14C07D401/14A61K31/519
CPCC07D401/14A61K31/519A61K31/522C07D403/14C07D473/04
Inventor 文智妍金柚琳朱埈皡李在宪张永佶
Owner HANMI FINE CHEM